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(57)	 ABSTRACT
Millimeter to nano-scale structures manufactured using a
multi-component polymer fiber matrix are disclosed. The use
of dissimilar polymers allows the selective dissolution of the
polymers at various stages of the manufacturing process. In
one application, biocompatible matrixes may be formed with
long pore length and small pore size. The manufacturing
process begins with a first polymer fiber arranged in a matrix
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to provide structural support and the polymer fiber matrix
selectively dissolved away leaving only the long polymer
fibers. These may be exposed to another product, such as a
biocompatible gel to form a biocompatible matrix. The poly-
mer fibers may then be selectively dissolved leaving only a
biocompatible gel scaffold with the pores formed by the
dissolved polymer fibers. The scaffolds may be used in,
among other applications, the repair of central and peripheral
nerves. Scaffolds for the repair of peripheral nerves may
include a reservoir for the sustained release of nerve growth
factor. The scaffolds may also include a multifunctional poly-
electrolyte layer for the sustained release of nerve growth
factor and enhance biocompatibility.
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HIGH ASPECT RATIO TEMPLATE AND
METHOD FOR PRODUCING SAME FOR
CENTRAL AND PERIPHERAL NERVE
REPAIR
CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a continuation-in-part of, and claims the
benefit of priority of, U.S. application Ser. No. 11/200,982,
filed Aug. 10, 2005, which claimed the benefit of priority of
U.S. Provisional Application Ser. No. 60/600,454, filed Aug.
11, 2004, U.S. Provisional Application Ser. No. 60/639,462,
filed Dec. 28, 2004, and U.S. Provisional Application Ser. No.
60/680,435, filed May 12, 2005. This application also claims
the benefit of priority of co-pending U.S. Provisional Appli-
cation Ser. No. 60/967,091, filed Aug. 31, 2007. The various
priority applications are incorporated by reference herein as if
set forth in their entirety.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH OR DEVELOPMENT
The invention described herein was made in the perfor-
mance of work under a NASA contract, and is subject to the
provisions of public law 96-517 (35 U.S.C. §202) in which
the Contractor has elected to retain title.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is directed generally to microtech-
nology/nanotechnology and, more particularly, to fabricating
biocompatible scaffolds with highly-ordered arrays of high-
aspect ratio conduits and to fabricating nano-scale templates
with highly-ordered arrays of high-aspect ratio conduits. The
biocompatible scaffolds may be used in, among other appli-
cations, central and peripheral nerve repair.
2. Description of the Related Art
Conventional machining technologies have long been used
to manufacture components for a variety of applications.
However, conventional techniques are limited to certain types
of materials (e.g., metal) and face fundamental limitations in
the size of the components.
For example, it is desirable in some applications to have a
structure that contains pores or conduits with a very small
diameter. Many applications that require small pore size also
require a relatively long pore length. Known techniques for
creating such high-aspect ratio pores are not suitable for a
number of reasons. Mechanical drilling is not gentle enough
to fabricate structures with thin walls and cannot be used to
achieve holes with a diameter <100 micrometers (µm).
Photolithography is not capable of producing features hav-
ing out of plane depth exceeding 0.1 millimeters (mm). Stan-
dard photolithographic techniques, used for patterning semi-
conductor devices, cannot produce high-aspect ratio pores.
The maximum achievable pore length of a standard photo-
lithographic patterning is typically <0.1 millimeters (mm),
and is limited by the maximum achievable thickness of photo
resist. Alternatively, LIGA is a lithography process utilizing
synchrontron radiation that may be capable of generating
higher aspect ratio pores, but is cost prohibitive. This is par-
ticularly important if the nano-scale device is disposable.
Laser drilling is generally not compatible with bio-poly-
mer gels, which may be as much as 97% water. In addition, it
is difficult to achieve high intensity at a spot size <100 µm
2
with laser drilling. Dye extrusion is also an incompatible
process for bio-polymer gels at a length scale in the 10 micron
range.
Accordingly, it can be appreciated that there is a significant
5 need for a process compatible with materials and capable of
patterning high-aspect ratio features ranging from the nanom-
eter to millimeter scale. The present invention provides this,
and other advantages as will be apparent from the following
detailed description and accompanying figures.
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BRIEF DESCRIPTION OF THE SEVERAL
VIEWS OF THE DRAWING(S)
The file of this patent contains at least one drawing
15 executed in color. Copies of this patent with color drawing(s)
will be provided by the patent and Trademark Office upon
request and payment of the necessary fee.
FIG. 1 is an enlarged perspective view of a biocompatible
scaffold.
20	 FIG. 2 illustrates implantation of the scaffold of FIG. 1 at
the site of a spinal cord injury.
FIG. 3 illustrates a process used to create the biocompatible
scaffold of FIG. 1.
FIG. 4 is a photograph of a sample of the biocompatible
25 scaffold of FIG. 1.
FIGS. 5A-5E illustrate an alternative embodiment of a
biocompatible scaffold and demonstrate uniform pore struc-
ture.
FIGS. 6A-6C are photographs of slides demonstrating
3o nerve growth using the biocompatible scaffold of FIG. 1.
FIG. 7 is a photograph of a slide demonstrating nerve
growth in multiple channels of the biocompatible scaffold of
FIG. 1
FIGS. 8A-813 are photographs of slides demonstrating an
35 improvement of nerve growth using the biocompatible scaf-
fold of FIG. 1.
FIG. 9 is a photograph of a slide demonstrating vascular
regeneration in multiple channels of the biocompatible scaf-
fold of FIG. 1
40	 FIG. 10 illustrates alternative embodiments of cross-sec-
tional areas of the biocompatible scaffold of FIG. 1.
FIG. 11 illustrates aprocess for creating a nano-scale struc-
ture.
FIG. 12 illustrates a highly ordered array of nano-scale
45 conductors created using the process of FIG. 11.
FIG. 13 are photographs of a magnified nanopore array.
FIG. 14 a f shows a 100/200 scaffold cross-sectional
analysis of a 7.5 mm long scaffold. Lower magnification
micrographs a, c, and e are taken at 2, 3.75 and 5.5 mm along
50 the longitudinal axis of the scaffold, respectively. The scale
bar represents 200 microns. Higher magnification micro-
graphs b, d and f are also taken at 2, 3.75 and 5.5 mm along the
longitudinal axis of the scaffold, respectively.
FIG. 15 a f shows a 501150 scaffold cross-sectional analy-
55 sis of a 7.5 mm long scaffold. Lower magnification micro-
graphs a, c, and e are taken at 2, 3.75 and 5.5 mm along the
longitudinal axis of the scaffold, respectively. The scale bar
represents 200 microns. Higher magnification micrographs b,
d and f are also taken at 2, 3.75 and 5.5 mm along the
60 longitudinal axis of the scaffold, respectively. The white
boxes highlight a cluster of four channels that extend from
end to end.
FIG. 16 a f shows a 40/280 scaffold cross-sectional analy-
sis of a 7.5 mm long scaffold. Lower magnification micro-
65 graphs a, c, and e are taken at 2, 3.75 and 5.5 mm along the
longitudinal axis of the scaffold, respectively. The scale bar
represents 200 microns. Higher magnification micrographs b,
US 8,075,904 B2
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d and f are also taken at 2, 3.75 and 5.5 mm along the
longitudinal axis of the scaffold, respectively.
FIG. 17 is a plot comparing the effect of channel porosity
per unit volume of scaffold as a function of the ratio of
channel diameter to wall thickness. The solid line represents 5
the values predicted by the hard cylinder model for close
packed arrays of hard cylinders.
FIG. 18 shows a 1 cm by 1 cm by 1 cm cubic scaffold
fabricated using 40/280 templates.
FIG. 19 shows time release scaffolds. The upper portion of i0
the figure illustrates the location and configuration of the
scaffold in relation to the peripheral nerve to be repaired. The
middle portion of the figure illustrates the detailed features of
the scaffold in interaction with the peripheral nerve being 15
repaired. The bottom portion of the figure shows the cross-
section of the scaffold.
FIG. 20 shows a time release scaffold with open-ended
sleeves and a hexagonal close-packed array of channels at the
center.	 20
FIG. 21 a-b shows a TYGONO (polyvinyl chloride ther-
moplastic polymer) outer reinforcing tube for the biocompat-
ible agarose scaffold. The TYGONO (polyvinyl chloride
thermoplastic polymer) tube prevents fracture of the scaffold
and facilitates the attachment of the tissue to be repaired to the 25
scaffold. FIG. 21a shows a side view of the reinforcing tube.
FIG. 21b shows an end view with the biocompatible agarose
scaffold being deployed inside the TYGONO (polyvinyl
chloride thermoplastic polymer) outer reinforcing tube.
FIG. 22 a-c shows the protein release characteristics of two 30
separate Multifunctional Polyelectrolyte Layers (MPL) when
deployed on the biocompatible scaffolds of the present inven-
tion. FIG. 22a shows the chemical structures of the MPL.
FIG. 22b shows an MPL initiated with protein and FIG. 22c
shows an MPL initiated with branched polyethylenimine 35
(BPEI).
FIG. 23 is an SEM micrograph image of a BPEI(PAA/
PEG)5 [(PAA/BSA)50 1 MPL which was fabricated onto 3%
(w/v) agarose.
FIG. 24 shows the change in absorbance of a BPEI(PAA/ 40
PEG)5 [(PAA/BSA)„] MPL-loaded hydrogel as a function of
an increasing number of PAA/BSA layers.
FIG. 25 a-b shows fibroblast adhesion behavior on PAA/
PEG multilayers deposited on a plane glass substrate.
FIG. 26 a-b shows two micrographs of images of BPEI 45
(SPS/PDAC) multilayer coatings fabricated onto agarose
matrices.
FIG. 27 a-b shows fibroblast adhesion behavior on (PDAC/
SPS) multilayers on a plane glass substrate.
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be manufactured in a way that permits the introduction of
neurotrophic agent to promote nerve growth.
In another application, nano-scale structures provide a
highly ordered nanowire or nanoconduit array. In this
embodiment, extremely high aspect ratio structures can be
economically achieved. The process described herein pro-
duces highly ordered arrays of cylindrical pores that can be
greater than one millimeter in length with an aspect ratio
(length/diameter) greater than ten. In practice, the process has
been used to produce 200 µm diameter holes in excess of 3
mm in length (an aspect ratio >150). The structures described
herein are constructed with polymer constituents that may be
selectively removed. Common construction techniques used
in fiber optic technology may be employed to produce elon-
gated bare polymer fibers or clad polymer fibers.
In another application, scaling-up of the scaffolds is dem-
onstrated for use in a broader range of clinical applications
involving nerve repair. In this application, scaffolds are pro-
vided with channels up to and beyond 1 cm in length with face
dimensions in the 1 cm2 range.
In another application, scaffolds are provided that are par-
ticularly useful for the repair of peripheral nerves. In this
application, a reservoir is incorporated into the construction
of the scaffold from which growth factor diffuses across the
agarose hydrogel walls in a time-release manner. This design
allows for the prolonged and sustained axonal regeneration
due to the continued presence of growth factor.
As will be described in greater detail herein, the selective
removal of polymer fibers creates pores or apertures whose
length, diameter, shape, and spatial arrangement can all be
carefully controlled. Instead of using conventional tech-
niques described above, the multi-component polymer fiber
templates described herein utilize dissimilar polymers that
are selectively dissolved in various solutions. There are sev-
eral unique advantages to the process described herein. The
chemistry involved does not generally expose the materials to
aggressive chemical etchings or subject them to mechanical
shear in tensile stresses that result from an extrusion process,
as described above. The process does not involve mechanical
or laser drilling, which are ineffective at the nano-scale. Fur-
thermore, the process is effective with biocompatible compo-
nents. Some standard manufacturing techniques, such as laser
drilling, is not effective with biocompatible components,
such as gels. Furthermore, the process described herein is cost
effective.
Example One
Biocompatible Scaffold
50
DETAILED DESCRIPTION OF THE INVENTION
	
	 Spinal cord injuries impact approximately 10,000 Ameri-
cans each year, usually cause lifelong disability due to the
	
The present disclosure is directed to an economic process 	 inability of the central nervous system (CNS) to regenerate
	
for a template or scaffold that may be used in a variety of	 naturally. However, while a cure for this devastating condi-
applications. The scaffold can achieve a highly ordered high- 55 tion remains elusive, the level of understanding of the primary
	
aspect ratio architecture useable in a variety of applications. 	 and secondary responses involved in spinal cord injury con-
	
The scaffolds contain conduits that can range from a diameter 	 tinues to increase. Regeneration of axons through a lesion site
	
of 100 nm to a diameter of 1 mm. Solely by way of example, 	 has been shown in experiments, usually as the result of neu-
	
and not by way of limitation, a typical scaffold according to 	 rotrophins and/or support cells to the site of the injury. How-
an embodiment of the present invention may have conduits 60 ever, it is typically random and, therefore, the chance of
	
with diameters ranging from 1 to 1000 microns, and more	 functional reconnection is minimal. Consequently, potential
specifically from 50 to 300 microns.	 strategies for effective regeneration are evolving, such as the
	
In one application described herein, the structure may be 	 use of a nerve guidance channel. The ideal nerve guidance
	
used to provide a neurological scaffold to assist in the regen- 	 channel must have several properties. First, it must be bio-
eration of nerve fibers in spinal cord injuries. In this applica-  65 compatible, with degradation products that are neither toxic
	
tion, the scaffold has the necessary biocompatibility to permit 	 nor immunoreactive in the CNS environment, and degrade
	
implantation at the site of the CNS injury. Furthermore, it can 	 slowly enoughto provide a physical scaffold for regeneration,
US 8,075,904 B2
5
but quickly enough to avoid any unpredictable long-term
effects of having foreign substances in the body. Second, it
must have appropriate adhesiveness and capable of hosting
neurotrophic factors with transmembrane signaling proper-
ties to stimulate axonal growth. Third, it should guide regen-
erating axons physically via predefined pathways and/or
chemically via neurotrophic factor gradients through the
channel.
The process described herein permits fabrication of highly
ordered monodisperse pores in extracellular matrices. The
term "monodisperse" refers to the fact that the pores have
uniform size. The ability to produce uniform pore size per-
mits close-packing of pores and results in a high-porosity
scaffold, which is desirable for nerve regeneration applica-
tions. In an exemplary embodiment, the pores are cylindrical
and parallel with diameters that can range from tens of
microns to hundreds of microns with lengths exceeding sev-
eral millimeters. As will be described below, the templated
extracellular matrix may be readily used to assist in axonal
regeneration following spinal cord injury.
For applications in axonal regeneration, it is necessary to
implant a biocompatible scaffold that directs the nerve
growth in the desired orientation. FIG. 1 diagramatically
illustrates a biocompatible nerve regeneration scaffold
designed specifically for experiments aimed at repairing cen-
tral nervous system injuries in rats. FIG. 2 illustrates the nerve
regeneration scaffold positioned in the spinal column. In this
particular application for nerve regeneration in rats, the scaf-
fold should have close packed pores (>50% pore volume),
exceed two millimeters in length, and have approximately 1
µm to >100 µm diameter conduits.
In experiments, it has been determined that a satisfactory
scaffolding material can be manufactured from agarose,
which is an inert polysaccharide. Agarose forms a stable helix
structure upon thermal polymerization to thereby create a
robust gel. Agarose is typically a liquid above 83° C. and
forms a gel below 40° C. Those skilled in the art will appre-
ciate that the biopolymer gels like agarose are mo stly water. A
typical gel maybe 97% water. The process described herein is
compatible with biopolymer gel processing.
To stimulate axonal regeneration, the scaffold must contain
the appropriate neurotrophic factors at the time of implanta-
tion. Pores within the agarose gel may be filled with an
extracellular matrix such as Matrigel® or Fibrin, which are
capable of hosting nerve-growth stimulating molecules or
cells such as Brain Derived Neurotrophins (BDNF) or Bone
Marrow Stromal (MSC) cells. Other neurotrophic agents may
be used in place of or in addition to BDNF or MSC cells.
The process of generating the agarose scaffold requires
multiple steps, illustrated in FIG. 3. The first process involves
the fabrication of a polymer fiber template. The fiber template
illustrated at step one comprises two dissimilar polymer
fibers. In one embodiment, polystyrene (PS) fibers are sur-
rounded by a polymethylmethacrylate (PMMA) matrix. The
PS fibers may be arranged in a desired spatial arrangement
within the PMMA matrix. Other polymers can be satisfacto-
rily used in place of the PMMA and/or the PS.
As discussed above, conventional techniques for optical
fiber manufacturing may be employed. A fiber template may
originally start with a large array of approximately one-half
inch in diameter. The selected polymers have similar visco-
thermal characteristics. The fiber template is heated and lat-
eral pressure applied to the sides of the large diameter bundle.
The bundle may be drawn out under heat and pressure. Those
skilled in the art will appreciate that as the fiber template
bundle is drawn out, the diameter of the bundle and embedded
6
PS fibers decreases. With this process, it is possible to achieve
diameters for the PS fibers less than 100 mu.
At step one in FIG. 3, a fiber template 100 has been manu-
factured in accordance with the techniques described above
5 so that the diameter of the embedded PS fibers equals the
diameter of the desired pore size. The PS fibers are oriented
along a longitudinal axis 102 of the fiber template 100. In the
first step, a slice 104 of the fiber template 100 is cut to the
desired length of the final product. For applications as a nerve
to regeneration scaffold, the fiber template slice 104 may be
approximately 2 mm in length. In this application, a diamond
saw may typically be used to cut the template to the desired
length. Sanding or polishing of the cut surfaces is typically
15 required to provide smooth working surfaces.
In step two, end caps 110 are chemically bonded to the face
of the fiber template slice 104. In one embodiment, the end
caps 110 are polystyrene sheets that will chemically bond
with the PS fibers within the fiber template slice 104. An
20 upper face 112 of the fiber template slice 104 is dipped in
toluene/acetone and one end cap 110 chemically bonded to
the upper face. The process is repeated by dipping a lower
face 114 of the fiber template slice 104 in toluene/acetone and
chemically bonding the second end cap 110 to the lower face.
25 The end caps 110 provide structural support and keep the
PS fibers in place during the remaining manufacturing pro-
cess. In addition, the PS end caps 110 serve to assure that the
pores in the biocompatible scaffold remain open at the end of
the processing.
30 In step three, the fiber template slice 104 and attached end
caps 110 are cut into columns 118 that approximately the final
desired dimension of the biocompatible scaffold.
Step four illustrates a single column 118 placed in a solu-
tion that selectively dissolves the PMMA fiber cladding leav-
35 ing only the PS fibers and PS end caps 110 intact. Those
skilled in the art will recognize that multiple columns may be
processed in a single batch. Furthermore, although not illus-
trated in FIG. 4, a polymer side plate may be chemically
bonded to the end caps 110 of the column 118 to provide
4o additional structural support. The end caps 110 of multiple
columns may be chemically bonded to a single side plate to
simplify the production of multiple scaffolds.
In the embodiment discussed herein, the PMMA matrix is
dissolved by placing the column 118 in a propylene carbonate
45 bath 120 at 45° C. for approximately 24 hours. This process is
repeated three separate times with fresh solvent to assure
complete dissolution of the PMMA matrix. Although FIG. 1
illustrates the processing of only a single column 118 at step
four, in practice, it has been shown that six template columns
50 118 may be processed in approximately 50 cc of the propy-
lene carbonate bath 120 in the process described above. Fol-
lowing the removal of the PMMA matrix, a washing step may
be used to remove any residual traces of the polypropylene
carbonate solution.
55 Following the removal of the PMMA matrix, the column is
placed in a permeate liquid biopolymer gel bath 122 at
approximately 80° C., as illustrated in step five of FIG. 3. As
noted above, agarose is a polysaccharide well suited for this
application. At 80° C., the agarose is in liquid form and
60 permeates throughout the PS fibers to form a biocompatible
matrix surrounding the PS fibers. Ultrasound energy may also
be applied to the bath 122 to provide uniform permeation and
to eliminate possible bubbles in the agarose liquid. In an
exemplary embodiment, the bath 122 is sealed to prevent
65 contamination and placed in a water-sonicating bath (not
shown) at approximately 90° C. for approximately 1-2 min-
utes.
US 8,075,904 B2
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After sonification, the bath 122 is removed from the water
bath (not shown) and allowed to cool to room temperature. At
room temperature, the agarose bath 122 forms a gel in
approximately four hours.
In step six, excess agarose gel may be removed with a knife
blade, scalpel, sander, or other suitable instrument. Following
the removal of excess agarose, the column 118 is placed in a
solution that selectively dissolves the PS fibers and the PS end
caps 110 from the column 118.
As noted above, thePS end caps 110 serve to assurethat the
pores in the biocompatible scaffold remain open when the PS
fibers are dissolved at the end of the process. Because the fiber
template slice 104 is cut to the desired length at the start of the
manufacturing process, there is no need to cut the column 118
after the pores have been removed by dissolving the PS fibers.
Cutting to length after the pores have been formed could lead
to a collapse of the walls. The chemical processing to form
pores of the desired length avoids mechanical damage that
may occur with other technologies.
In an exemplary embodiment, the PS fibers and PS end
caps are dissolved by placing the column 118 in a tetrahydro-
furan bath 124 at room temperature for approximately 24
hours. This process is repeated approximately three times. As
noted above, batch processing of columns is possible. It has
been determined that approximately 50 cc of tetrahydrofuran
is sufficient to dissolve the PS fibers and PS end caps 110 for
approximately six columns. At the end of this process, only
the agarose scaffold remains. The PS fibers that extended
through the agarose gel are dissolved in the tetrahydrofuran
bath 124 to create an array of pores in the agarose scaffold.
The pores have the diameter and physical arrangement of the
PS fibers and extend through the length of the column 118.
In the photo shown in FIG. 4, the nerve regeneration scaf-
fold has approximately 200 µm pore size and approximately
100 µm wall thickness. In the embodiment illustrated in FIG.
4, the nano-scale structure has a porosity of approximately 44
percent and has a substantially circular cross-section. In a
subsequent design, illustrated in FIG. 5A, the scaffold has
approximately 200 µm pore size, 33 µm wall thickness, to
achieve a porosity of approximately 60 percent. The wall
thickness in the described process enables the high pore vol-
ume. FIG. 5A illustrates the scaffold with the fibers still in
place. FIG. 5B illustrates the scaffold of FIG. 5A following
the removal of the polymer fibers leaving a honey-comb pore
arrangement with pores. A three dimensional (3-D) recon-
struction reveals substantially uniform pore structure from
end to end. FIGS. 5C-5E are cross-sections of the scaffold at
various depths. In these images, individuals pores have been
numbered so that changes in structure may be detected.
FIGS. 6-8 are photographs of slides illustrating nerve
growth using the biocompatible scaffold. In an exemplary
embodiment, the pores may be filled with a nerve growth
factor, brain derived neurotrophic factor (BDNF), as noted
above. In other embodiments, the scaffold pores may be filled
with genetically engineered marrow stromal cells (MSC) that
secrete brain derived neurotrophic factor (BDNF). For
experimental purposes, the MSC may also be engineered to
express a green fluorescent protein (GFP) reporter gene.
Those skilled in the art will appreciate that GFP fluoresces
under a microscope with an appropriate light source, allowing
identification of modified cells that have been implanted
within the scaffold.
A rat model of spinal cord injury was used to test the ability
of scaffolds to stimulate and guide axonal regeneration in
vivo. Spinal cord lesions were created by aspirating tissue at
the C3 vertebra level (resulting in a cavity matching the
dimensions of the scaffold: 2 mm long, 1.5 mm wide, and 1.4
8
mm deep) and subjects were divided into three groups. The
first group was treated with unfilled scaffolds, a second group
was treated with scaffolds filled with a non-BDNF secreting
MSCs (GFP-MSCs) and a third group was treated with scaf-
5 folds filled with BDNF secreting MSC (BDNF-GFP-MSCs).
Thirty days after implantation, the rats were perfused with
paraformaldehyde and the spinal cords were sectioned in the
sagittal plane.
The images in FIGS. 6-8 have different magnifications. A
l0 
scale bar in each image equals 200 µm. FIG. 6A illustrates
nerve growth using the group with empty scaffolds. FIG. 6B
illustrates the results with scaffolds with the non-BDNF
secreting MSC (GFP-MSC). FIG. 6C illustrates results with
15 scaffolds filled with BDNF secreting MSC (BDNF-GFP-
MSC). A comparison of FIGS. 6A-6C indicates that the scaf-
folding alone (FIG. 6A) provides some basis for axonal
growth while the introduction of neurotrophic agents (FIG.
6C) promotes a significant increase in nerve growth.
20 FIGS. 6A-6C illustrate nerve growth in a single channel of
the nerve regeneration scaffold. FIG. 7 illustrates nerve
growth in multiple channels of the nerve regeneration scaf-
fold. This demonstrates the effectiveness of the multi-lumen
nerve growth scaffold for promoting and directing nerve
25 regeneration.
Additional experiments were conducted to demonstrate the
value of the scaffold to assist in the development of functional
nerve growth. In FIG. 8A, immunolabeling against GFP is
used to highlight implanted BDNF-secreting MSCs, while in
30 FIG. 8B immunolabeling against Neurofilament (NF), a gen-
eral axonal marker, is used to highlight axon growth. The
images on the left in FIGS. 8A-B were taken from animals
which received BDNF-secreting MSCs within a scaffold,
while the images on the right in FIGS. 8A-B were taken from
35 animals which received BDNF-secreting MSCs without a
scaffold. Although both images demonstrate nerve growth,
the nerve growth utilizing the scaffold is highly linear and
organized while the non scaffold nerve growth is somewhat
random in nature.
40 For a successful nerve regeneration scaffold, vasculariza-
tion is necessary to both promote and sustain axonal growth.
FIG. 9 illustrates evidence of vascular regeneration within
implanted scaffolds. A scale bar in the image equals 100 µm.
FIG. 9 shows multiple channels in the nerve regeneration
45 scaffold and the areas indicated by the arrows show vascular
growth within those channels.
The scaffold illustrated in FIGS. 1-4 have pores with a
generally circular cross-section. However, those skilled in the
art will appreciate that other cross-section shapes may also be
50 readily produced. FIGS. 5A-5E illustrate a honey-comb
cross-section. FIG. 10 illustrates circular cross-section and
hexagon cross-section designs. Other shapes, such as rect-
angles, squares, or irregular shapes are also possible. The
present invention is not limitedby the specific cross section of
55 the shape of the pores.
Example Two
Ordered Array Nanodevice
60
The biocompatible scaffold described above has pore size
diameter in the 10 µm-200 µm diameter range. However, with
the application of the principles described herein, pore size
can be reduced to a much greater degree, depending on the
65 application. Experiments have shown that pore size may be
reduced to <10 run in diameter. The nanoscale template may
also have bio-applications, such as the nerve repair process
US 8,075,904 B2
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described above. Furthermore, at this scale, other applica-
tions are possible, as will be described in greater detail below.
A multi-component polymer fiber template may be used to
enable the selective deposition of dissimilar materials into
well defined arrays of nanoconduits or nanoconductors hav-
ing specific arrangements or configurations. This structure
permits applications, such as thermoelectric devices, or semi-
conductor-based devices. In these applications, positive and
negative conducting elements may be manufactured in the
nano-scale device.
In the process described below, a nanowire based thermo-
electric device is manufactured. In FIGS. 1-5, polystyrene
fibers were embedded in an ordered array within a PMMA
matrix. The bi-component polymer process of FIGS. 1-5 can
be extended to multi-component polymer fibers. In one
example of this application, two different polymer fibers are
embedded within a PMMA matrix. In an exemplary embodi-
ment, PS fibers and polyvinyl alcohol (PVA) polymer fibers
are arranged in a desired ordered array in a PMMA matrix. As
described above with respect to step one in FIG. 3, the ordered
array may initially have a large diameter and, through the
application of heat and pressure, be drawn out until the PS and
PVA fibers have the desired diameter.
In step one, shown in FIG. 11, a slice of a multi-component
nano fiber matrix (MCNFM) 130 is cut and polished. As
previously discussed, a diamond saw may be suitable for
cutting a slice having the desired pore length. The MCNFM
slice 130 differs from the fiber template slice 104 (see FIG. 3)
in that it contains two dissimilar polymer fibers contained
within the PMMA matrix. In the example illustrated in FIG.
11, the MCNFM slice 130 comprises an ordered array of PVA
fibers 132 and PS fibers 134.
At step two, the surface of the polished MCNFM slice 130
is covered with a conductive layer 138. Conventional tech-
niques, such as sputtering, can be used to apply the conduc-
tive layer 138 to the MCNFM slice 130.
In step three, the sample is flipped over to better illustrate
the reaming process steps. However, this step is not required
in practice because the subsequent steps of dissolving fiber
cores will occur irrespective of the orientation of the
MCNFM slice 130
In step four, the MCNFM slice 130 is placed in water.
Those skilled in the art will appreciate that PMMA polymer
and PS polymer do not dissolve in water. However, the PVA
fibers are soluble in water and are therefore removed in step
four. The selective removal of the PVA fibers 132 leaves an
ordered array of pores in the MCNFM slice 130 in place of the
PVA fibers.
In step five, a thermoelectric material is deposited in the
pores created in step four. That is, a thermoelectric material is
deposited within the pores created by the removal of the PVA
fibers 132. In an exemplary embodiment, electrochemical
deposition (ECD) is used to deposit a p-type thermoelectric
material in the pores created by the removal of the PVA fibers
132.
In step six, a passivation layer is added to passivate the
p-type material to protect it in subsequent processing steps.
This process is well known in the art and need not be
described in greater detail herein.
In step seven, the MCNFM slice 130 is placed in a second
solution to dissolve the PS fibers 134. In an exemplary
embodiment, the MCNFM slice 130 may be placed in a
solution of tetrahydrofuran bath to remove the PS fibers 134.
Those skilled in the art will appreciate that PMMA and PVA
are insoluble in tetrahydrofuran. Thus, steps 4 and 7 could be
reversed. That is, the MCNFM slice 130 could have been
10
placed in the tetrahydrofuran bath in step 4 to dissolve the PS
fibers 134 rather than the PVA fibers 132.
In step eight, the pores created by the removal of the PS
fibers 134 are filled with a semiconducting material. In an
5 exemplary embodiment, an ECD process is used to deposit
n-type thermoelectric material in the pores created by the
removal of the PS fibers 134 in step seven.
In step nine, the passivation layer over the p-type material
is removed and, in step ten, an ECD process may be used to
io deposit interconnecting conductors between the p-type mate-
rial and n-type material to create the desired electrical array.
Thus, the multi-component process illustrated in FIG. 11 may
be created with a long pore length and high aspect ratio
architecture that cannot be achieved by conventional pro-
15 cesses
Depending on the application, the matrix surrounding the
PVA fibers 132 and PS fibers 134 can be removed or left
intact. If the matrix is left intact, a polymer matrix, such as
PMMA, may be replaced by a different matrix structure hav-
20 ing the desired similar viscothermal characteristics that allow
processing to generate the basic MCNFM material, as
described above.
In the example described in FIG. 11, the matrix comprises
PMMA. It is known that PMMA has low thermal conductiv-
25 ity. In applications where heat generation is not an issue, the
PMMA matrix may be left intact to provide increased struc-
tural integrity. In applications where heat dissipation is desir-
able, an additional step (step 11) can be added to place the
device in a final bath to dissolve the surrounding matrix. If the
30 matrix is PMMA, a propylene carbonate bath may be used.
FIG. 12 illustrates a finished product in which a large
ordered array of nanoconduits have been processed (e.g.,
filled with semiconducting material) and interconnected with
conductive elements.
35 Those skilled in the art will appreciate that the process
described in FIG. 11 may be altered. For example, the
removal of PVA fibers 132 and PS fibers 134 may be reversed
as described above (i.e., reverse steps 4 and 7). Alternatively,
PMMA maybe used for the core fibers and placed in a matrix
40 of, by way of example, polystyrene. Thus, the specific poly-
mers utilized for the various components illustrated in FIG. 9
maybe interchanged. Furthermore, the deposition of p-type
material in the pores created by the removal of PVA fibers 134
could be substituted with n-type material in step five. In this
45 embodiment, step eight would involve the deposition of
p-type material. Thus, those skilled in the art will appreciate
that the exemplary embodiment of FIG. 11 may be readily
altered. The present invention is not limited by the specific
fibers or the specific sequence of steps described herein.
50 Other variations are also possible. For example, the PVA
fibers 132 and PS fibers 134 are all the same diameter in FIG.
11 resulting in uniform pore diameter. However, the original
MCNFM slice 130 may contain fibers of different diameters.
For example, in one system architecture it may desirable to
55 interconnect a number of the pores filled with semiconductor
material to a common conductor. To reduce current density
through the common conductor, it may have a larger diameter
polymer fiber at step 1 of the process resulting in a larger
diameter pore upon completion of the process.
60 In another example, it is known that the heat flux and
current density in N-type material is different from the heat
flux and current density in P-type material. Using the process
described herein, it is possible to adjust the diameter of the
PVA fibers 132 or the PS fibers 134 to compensate for the
65 differences in heat flux and current density. In this example,
all the PVA fibers 132 have the same diameter and all the PS
fibers 134 have the same diameter, but the diameter of the
US 8,075,904 B2
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PVA fibers is different from the diameter of the PS fibers.
Those skilled in the art will appreciate other configurations
requiring pores of different diameter may also be readily
implemented using the techniques described herein.
In yet another alternative embodiment, the multi-compo- 5
nent process of FIG. 11 may be replaced with the bi-compo-
nent process described in FIGS. 1-5. That is, a large area
matrix may be embedded with a single type of polymer fiber
to create a large ordered array of pores for other applications.
FIG. 13 illustrates a highly magnified (10,000x) image of 10
nanopores in a polymer matrix. The nanopores were pro-
duced with a process similar to that illustrated in FIG. 11, but
with a plurality of only one type of polymer fiber embedded in
a second polymer matrix. For example, PVA fibers may be
embedded in a PMMA matrix in step 1 shown in FIG. 11. The 15
PVA fibers may be dissolved to create the desired nanopore
arrangement of FIG. 13 simply by placing the matrix in water
to dissolve the PVA fibers. The inset in FIG. 13 provides
greater magnification (100,000x) to better illustrate the
ordered array of pores. 	 20
In this embodiment, a number of applications are possible.
For example, the nanopore array may be used as a filter. One
surface of the nanopore array can be placed in contact with
fluid, which passes throughthe pores, and thus filters based on
pore size.	 25
In an exemplary embodiment, the nanopore filter may be
used to filter water. In one embodiment, the pores may be
embedded or coated with an antibacterial agent. For example,
silver has known antibacterial qualities. Silver or a silver
compound could be embedded or coated along the length of 30
the nanopores at a concentration sufficient to provide the
desired antibacterial effect.
In yet another application, the nanopore structure of FIG.
13 could be used as conduits for electrical devices, such as
nanowires or the like. It is possible to achieve a density of 35
approximately 1xIO" pores per square centimeter. This
potentially provides a large, high-density conductor array.
As discussed above, a number of different polymers have
been satisfactorily employed in the processes described
herein. Table 1 below provides a partial list of polymers and 40
associated solvents. Those skilled in the art will appreciate
that other polymers may be employed in the manner
described above.
TABLE 1
	 45
Polymer/Solvent Pairs
Polymer	 Solvent
Polymethylmethacrylate 	 Propylene carbonate	 50
Polystyrene	 Tetrahydrofuran
Polyvinyl Alcohol	 Water
Example 3	 55
Scalability of the Scaffolds
In other embodiments described herein, it has been dem-
onstrated that scaffolds with channels 2 millimeters long 60
could promote and guide axonal regeneration through the
entire length of the scaffold. The present embodiment
involves scaling the technology to dimensions with a broader
range of clinical applications, which involve axonal regen-
eration and guidance up to and beyond 1 cm long with face 65
dimensions (the scaffold plane perpendicular to the longitu-
dinal axis of the channels) up to and beyond the 1 cm2 range.
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The scaffolds of the present embodiment were fabricated
following the same procedures as in Example 1, above, with
the primary exception of the template dimensions. The pre-
vious embodiments used Multicomponent Fiber Bundles
(MCFBs) with 200 micron diameter fiber cores separated by
100 micron thick walls in a hexagonal packed arrangement.
The templates/scaffolds of the present embodiment have face
dimensions exceeding 1 cm2 with channels up to 1 cm in
length. A variety of nerve guidance scaffold channel diam-
eters and wall thicknesses arereported to further demonstrate
the range of dimensions possible with this technology.
Multi-component Fiber Bundles (MCFB) were fabricated
by Paradigm Optics Inc. and consisted of various diameter
Polystyrene (PS) cores surrounded by a continuous matrix of
Polymethylmethacrylate (PMMA). The solvent usedto selec-
tively etch the various fiber bundle constituents was pur-
chased from Alfa Aesar and the PS endcaps attached to the
fiber bundles were cut from polystyrene boxes purchased
from VWR. Scaffolds were fabricated using distilled water
and agarose from Sigma.
The MCFB used to fabricate nerve guidance scaffolds con-
sisted of PS fiber cores surrounded by a continuous matrix of
PMMA with a typical, as received length of 10 cm in the
longitudinal direction. Typical MCFB cross sections were
rectangular, in the range of 4-6 mm along one edge and 12 mm
to 18 mm on another with the exception of the 40 micron
wall/280 micron PS fiber core MCFB, which measured 20
mm by 20 mm. The range of PS fiber core diameters and
spacing between cores is listed in Table 1.
TABLE 1
PS fiber core diameters and snacina between cores
Cross Section
Sample	 Wall (µm) Channel (µm)	 (mm x mm) Length (mm)
100/200	 100	 200	 4 x 5 rectangle	 7.5
501150	 50	 150	 6 x 6 square	 7.5
40/280	 40	 280	 10 x 10 square	 7.5
The MCFBs were cut with a diamond saw to the desired
length, finished with 600 grit sand paper, and rinsed with
ethanol. PS sheets with dimensions matching the MCFB tem-
plate were cut from 1.0 mm thick sheets of PS and bonded to
the ends of the MCFB. Bonding was achieved by immersing
the PS sheets in Cyclohexane (Alfa Aesar) at 45 C for 10
seconds and quickly pressed on the ends of the MCFB. PS
rectangles were bonded to each of the MCFB ends this way.
Cyclohexane was specifically selected to selectively and par-
tially dissolve only the PS fibers and the PS rectangles so that
the PMMA matrix remained intact. The same process was
usedto bond PS side supports spanning from PS end cap to PS
end cap (end caps refer to the previously mentioned PS rect-
angles), which give the templates rigidity in the latter steps of
processing. The template assemblies are then immersed in a
propylene carbonate (PC)/acetonitrile (ACN) 80/20 vol/vol
% solvent bath at 45 C and stirred with a magnetic stir bar for
24 hours (repeated 3 times). The addition of 20 vol % ACN
increased the solubility of PMMA enough to achieve reason-
able etch rates to allow etching templates that were signifi-
cantly larger compared to the other embodiments. Adding
more the 20 vol % ACN was deleterious in that PS compo-
nents began dissolving along with the PMMA. Approxi-
mately 100 ml of etch bath is used for 1 cc of template. Since
PS is not soluble in the PC/ACN etch bath the PMMA matrix
is selectively removed leaving only the PS fibers, end caps
and side supports intact. Once the PMMA is removed the fiber
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template is rinsed in distilled water three times (approxi-
mately 100 ml ethanol for each ml of template) for 15 minute
each wash. The fiber templates are then immersed in a 3.0%
wt. % agarose hydrogel 97% wt. % distilled water solution at
80 C, immediately followed by one minute of centrifugation
at 5000 rotations per minute for one minute, and allowed to
cool to room temperature (centrifugation facilitates agarose
hydrogel gel permeation through the template). The incorpo-
ration of a centrifugation step assures complete permeation of
the liquid agarose hydrogel through the template. Selective
removal of all the PS template components (fibers and end-
caps) is achieved by immersing the agarose hydrogel penne-
ated template in a tetrahydrofuran (THF Alfa Aesar) bath at
room temperature for 24 hours (approximately 100 ml THF to
each ml of template). The agarose hydrogel scaffolds were
then rinsed in an acetone bath to remove residual PS followed
by a final immersion and storage in distilled water.
Scaffold microstructural analysis was conducted to char-
acterize features such as channel and wall dimensions, calcu-
late channel volume percentage per unit volume scaffold and
channel/wall integrity and uniformity along the longitudinal
axis. Scaffolds were mounted in low gelling point agarose
hydrogel (low molecular weight agarose hydrogel Sigma
Aldrich#7067). To improve contrast for optical imaging, 0.02
vol % Single-wall carbon nanotubes are incorporated into the
agarose hydrogel scaffolds during the agarose hydrogel cast-
ing step. Scaffolds were immersed in 3 wt % low molecular
weight agarose hydrogel solutions at 60 C for 1 minute and
centrifuged at 5000 rpm for 1 minute. In this case, centrifu-
gation permeated the low molecular weight agarose hydrogel
through the scaffold channels. After cooling and gelation, the
mounted scaffolds were rigid enough to withstand mechani-
cal grinding or sanding. Grinding down to various depths
along the longitudinal axis of the scaffolds was achieved
using coarse sand paper (240 grit) and polished using fine
(1200 grit) sandpaper. Optical microscopy was conducted
using a Zeiss microscope illuminating the back side of the
mounted scaffolds using fluorescent white light.
The theoretical channel area (or channel volume per unit
volume of scaffold) was calculated based on the close-packed
hard cylinder model. The diagonal of the unit cell of a close-
packed array is referred to as the close-packed direction,
hence the spacing between cylinders is determined by the
surrounding cladding or wall thickness. The channel volume
percent per unit volume of scaffold was measured using his-
tograms, which typically included 1 square millimeter area
and approximately 100 to 200 channels.
The present embodiment thus involves the fabrication of
scaffolds to enable bridging through the damaged tissue and
reestablish nerve continuity. Precise control of scaffold chan-
nel size is enabled, allowing for separation between channels
and the maintainance of a high degree of ordering in the range
of millimeters to centimeters both perpendicular and parallel
to the direction of axon growth. The scaffolds are designed
and fabricated such that axon growth is consistent with the
native nervous system environment with regard to relative
position and density. The approach involves a patterning pro-
cess that uses wet chemical etching to selectively remove
polymer optical fibers while leaving the permissive axonal
growth substrate (agarose hydrogel) intact.
Increasing the scaffold dimensions from 1.5 by 1.5 by 2
mm long in previously described embodiments to up to 1 cm
by 1 cm by 1 cm long did require some modifications. As the
dimensions perpendicular to longitudinal length increase
beyond 5 mm, it becomes increasingly difficult to selectively
remove the PMMA cladding at the center of the templates.
This was mitigated by adding Acetonitrile (ACN) to the Pro-
pylene carbonate etch bath. ACN alone is too aggressive and
would etch the PS fibers along with the PMMA cladding,
hence only 20% vol % (enough to increase PMMA solubility,
but not enough to increase solubility with the PS fibers) was
5 added to increase solubility with PMMA to allow its complete
removal. A related issue involved permeating the molten aga-
rose hydrogel through the templates again as the dimensions
perpendicular to the longitudinal direction increased to
approximately 5 mm. Permeating the molten agarose hydro-
l0 gel through the larger templates was accomplished by centri-
fuging the fiber templates while immersed in molten agarose
hydrogel (80 C at 5000 rpm for 1 minute).
Images of the scaffolds listed in Table 1 detail the scaffold
15 micro-structures at various depths along their respective lon-
gitudinal axes at low and high magnification. For example,
micrographs in FIGS. 14 a,c and e represent the low magni-
fication cross sections at 2, 3.75 and 5.5 mm, respectively,
referenced from one end of the scaffold. Similarly, FIGS. 14
20 b, d andfrepresent higher magnification images at2,3.75 and
5 mm, respectively. The ordering in all the scaffolds is quasi-
hexagonal in that the fiber templates used are slightly dis-
torted during the fusing process (which results in a higher
packing density as described below). The walls and channels
25 of the scaffolds are within —1% of the fiber template dimen-
sions, thus indicating that the scaffolds form precise repli-
cates of the original PMMA matrix in the original un-etched
templates. It is also important to note that the order and
dimensional tolerance of the walls and channels are main-
30 tained throughout the entire cross section of all the scaffolds
shown in FIG. 14-16. There was concern that the inherently
weak agarose hydrogel material would not withstand the
rigors of processing as the scaffold walls decreased below
100 microns However, the 50 micron walls in the 501150 and
35 40 micron walls in the 40/280 scaffolds are intact and main-
tain their integrity throughout the entire cross section of their
respective scaffolds. The white boxes in the FIG. 15 highlight
a cluster of 4 channels with a square arrangement (slight
interruption in the hexagonal ordering due to slight distortion
40 of the fiber cores as noted above). The higher magnification
images in the right column (FIGS. 15 b, d and f) trace the
continuity of the channels through the length of the scaffold,
thus indicating that the channels are open from end to end.
Likewise, the walls in this cluster maintain their dimensional
45 tolerance, thus indicating that the scaffold maintains its
mechanical integrity along the length of the scaffold as well.
The same is true for the 100/200 and 40/280 scaffolds.
As discussed above, the channel volume per unit volume of
the scaffold increases as the channel diameter/wall thickness
50 increases. A maximum of 74% channel volume is reached
when the wall thickness is zero as predicted by the hexagonal
packed hard cylinder model. The channel per unit volume (or
area) is plotted against the channel/wall ratio in FIG. 17. The
solid black line represents the theoretical values for the hard
55 sphere model. Interestingly, all of the scaffold channel porosi-
ties exceed the predicted values and this is attributed to the
distortion mentioned above. The 100/200, 501150 and 40/280
scaffolds have channel porosities of 42, 52 and 70 percent.
These values are significantly higher than what has been
6o reported in literature where 35 vol % has been the highest
value achieved. The % channel volume is a key value in that
the higher the value the greater the likelihood of restoring the
native nerve networks.
A 1 cm3 scaffold was fabricated to demonstrate that all
65 dimensions can be scaled significantly compared to previous
work. The scaffold was fabricated using at 40/280 template.
As with the other similar scaffolds, this scaffold has the high
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degree of ordering and uniform channel/wall dimensions over 	 nature of agarose. Adhesives and glues cannot be used due to
the entire scaffold cross-section.	 the practical problem of blocking channels in the scaffold and
because any application such materials directly to the scaffold
Example 4	 can cause fracture. To address these issues, a biocompatible
5 reinforcing tube can be used on the outside of the templated
Time-Release Scaffold	 agarose scaffold as shown in FIG. 21.
"The surgical and medical product sold under the trade-
In another embodiment, the construction of time-release 	 mark TYGONO tubing, such as TYGONO S-50-HL and
scaffolds for the repair of peripheral nerves is demonstrated.	 S-54-HL medical tubing, is a biocompatible material made of
In order to sustain the growth of axons in peripheral nerves, 10 polyvinyl chloride (PVC) thermoplastic polymer with appro-
adequate growth factor must be present. Thus, we have devel- 	 priate mechanical properties to serve as the outer reinforcing
oped a novel scaffold design that incorporates a reservoir	 tube. Additionally, if sutures are needed, the TYGONO
within the walls of the scaffold to sustain delivery of nerve 	 (polyvinyl chloride thermoplastic polymer) tubing can be
growth factor.	 sutured. If a medical grade crazy glue is used for anchoring,
Time-release scaffolds according to this embodiment are 15 its texture is coarse enough for scaffold implantation. The
shown in FIG. 18. The top portion of the figure illustrates how	 tube is cut open, the scaffold is inserted, and the shape of the
the scaffold is ultimately to be surgically attached to the 	 tubing returns or recovers to its original shape. TYGONO
severed ends of a peripheral nerve injury. The middle portion	 (polyvinyl chloride thermoplastic polymer) tubing is
of the figure is a schematic that illustrates the details of the 	 approved for many medical applications and has been shown
concept. There are three essential features: 1) the open-ended 20 to be biocompatible in our peripheral nervous system, with
sleeves enable attachment to the severed peripheral nerves, 2)	 only a thin leptomeningeal layer after a 1 year implantation. If
the templated hexagonal array of nerve guidance channels,	 the anchoring point needs to be changed during surgery, the
and 3) the growth factor reservoir integrated into the outer	 TYGONO (polyvinyl chloride thermoplastic polymer) tub-
wall of the scaffold. The bottom portion of the figure illus- 	 ing can easily be cut to the appropriate lip size."
trates the cross section at mid span perpendicular to the lon- 25	 "TYGONO (polyvinyl chloride thermoplastic polymer)
gitudinal axis. At the center of the scaffold cross section, the 	 tubing of 1 mm inner diameter and 1.5 mm outer diameter is
channels guide the nerves. Growth factor delivery from the 	 used. A razor blade is used to cut the TYGONO (polyvinyl
reservoir to channels is controlled by diffusion through the 	 chloride thermoplastic polymer) tubing in a uniaxial manner.
agarose hydrogel walls. It is important to note that the entire 	 The tubing is opened and then stabilized with clamps on each
scaffold is comprised of agarose hydrogel and as such there 30 side. The scaffold is then implanted using only the surface
are no discontinuities between the channels and the reservoir 	 tension of the water and a flat forcept to place the scaffold into
other than the continuous, intrinsic pore network of the aga-	 the appropriate position. The tubing clamps are removed and
rose hydrogel. 	 the TYGONO (polyvinyl chloride thermoplastic polymer)
An example of the time-release reservoir scaffold design is 	 tubing returns to the original shape. A small amount of medi-
shown in FIG. 19. It is an all agarose hydrogel scaffold with 35 cal crazy glue may be applied along this seam to help stabilize
the open-ended sleeves and a close packed array of channels 	 the interface, but has not been proven to be necessary. Thus,
(100 wall/200 channel dimensions). In a separate experiment, 	 the scaffold is anchored inside of the TYGONO (polyvinyl
polystyrene coupons (that would mock the templates used to 	 chloride thermoplastic polymer) tubing with an evenly dis-
pattern the reservoirs) were suspended in molten agarose 	 tributed force. Generally, a 1 to 2 mm "lip" beyond each side
hydrogel such that the coupons were completely encapsu-  40 of the scaffold is used for anchoring the tissue to the
lated with agarose hydrogel upon cooling. Upon cooling and 	 TYGONO (polyvinyl chloride thermoplastic polymer) tub-
solidification, the agarose hydro gel/polystyrene coupon was 	 ing."
immersed in tetrahydrofuran (THE). The THE permeated the
interconnected pore network intrinsic to the agarose hydro- 	 Example 5
gel, and completely dissolved the polystyrene coupon leaving 45
a reservoir in its place.	 Multifunctional Polyelectrolyte Layer Coatings
The reservoir was integrated around the templated channel
network through the use of a cylindrically-shaped mold. The 	 It is desirable to deploy scaffolds capable of sustained
cylindrical mold was designed such that the polystyrene fiber	 release of neurotrophic growth factors (NGF) that exhibit a
template was centered in the middle of the longitudinal axis. 5o high degree of biocompatibility.
Molten agarose was cast into the mold such that it permeated 	 Accordingly, another embodiment of the instant invention
the polystyrene fiber network and the cylindrical mold. Upon 	 includes scaffolds coated with Multifunctional Polyelectro-
cooling, the assembly was immersed in THE to selectively 	 lyte Layers (MPL's). The MPL coatings are deposited on the
etch the polystyrene fibers. All subsequent steps were as	 surface of the scaffolds at low pH and are capable of incor-
described for other embodiments disclosed herein. The inner 55 porating proteins such as NGF. When the scaffolds are
diameter of the cylindrical mold was approximately 4-8 mil- 	 exposed to the body's pH near 7, the MPL coatings can be
limeters in diameter such that the agarose hydrogel surround- 	 designed to degrade, thus releasing the NGF in a controlled,
ing the templated region was in the 2-3 mm range. 	 time-release manner. Also, surface modification of hydrogel
In all of the scaffold embodiments described herein, two 	 components such as the inventive scaffolds has been shown to
issues to be aware of are the long-term fracture resistance of 6o reduce inflammatory response, thus increasing biocompat-
the scaffold and the interface between the scaffold and the	 ibility.
host's tissue. Scaffold fracture can occur due to shear and 	 The MPL coatings can be biodegradable or non-biodegrad-
tensile forces imposed by nearby muscle movements or 	 able. Biocompatible degradable MPL coatings on agarose
impacts to the surface of the host's skin. The characteristics of
	
hydrogel scaffolds provide two key functions. First, time-
the interface between the tissue to be regenerated and the 65 controlled NGF release over a period of weeks is possible
scaffold must also be considered. A severed nerve cannot be 	 because the growth factor, while initially bound up in the
stitched directly to the scaffold due to the relatively brittle	 MPL layer, is released as the MPL layer biodegrades. Also,
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the MPL layer is cytophobic during NGF release. Upon 	 FIG. 23 is an SEM micrograph image of a BPEI(PAA/PEG)5
completion of the NGF release, the surface then turns cyto-	 [(PAA/BSA)50] MPL which was fabricated onto 3% (w/v)
philic. These two functions allow sustained release of NGF 	 agarose. The image was taken after 4 weeks of ambient drying
and reduce undesirable cell adhesion onto the channel walls 	 of the MPL-coated agarose.
of the scaffold to permit/enable nerve growth. In contrast, 5	 We confirmed that protein was loaded onto the hydrogel in
non-degradable and non-biocompatible coatings provide a 	 the MPL coating process by looking for an increase in absor-
permanent cytophobic coating, but are not tuned for con- 	 bance at 280 mn with increasing number of bilayers of pro-
trolled release of NGF. 	 tein/PEG bilayers on agarose hydrogel. FIG. 24 shows the
MPL technology involves fabrication of sandwiched mul- 	 change in absorbance of a BPEI(PAA/PEG) 5 [(PAA/BSA)5o1
tilayers using three polymers, namely, polyethylene glycol io MPL-loaded hydrogel as a function of an increasing number
(PEG), polyacrylic acid (PAA) and protein (such as NGF).	 of PAA/BSA layers.
The basic fabrication process involves the use of a technique	 As discussed above, both PAA/PEG MPL's and SPS/
previously developed for film fabrication, namely, a layer-by-	 PDAC MPL's exhibit cytophobic behavior upon deposition
layer assembly process (Decker, Science, 1997). Two differ-	 onto hydrogel scaffolds.
ent sets of multilayers, namely H-bonded PAA/PEG multi- 15 The PAA/PEG coatings provide a cytophobic surface
layers and protein/PEG multilayers are deposited at pH of 2.0 	 depending on the number of bilayers. The lower the number
(of PEG and PAA) and pH of 3.0 (of protein) with varying 	 of bi-layers, the more cytophobic the films are. These multi-
individual numbers of bilayers. Alternate arrangements of
	
layers degrade over time and do not present a rigid substrate
these two different multilayers; with protein/PEG multilayers 	 for cell adhesion. MPL coatings (PAA/PEG and protein/PEG
sandwiched between the two PAA/PEG multilayers, form the 20 sandwiched multilayers) also present a cytophobic (cell resis-
backbone structure of MPL. In other words, protein/PEG and 	 tive) surface, essentially for the period in which they release
PAA/PEG multilayers are arranged alternatively in a stacking 	 the proteins from within the films. It is important to resist
fashion, on top of each other. The number of bilayers of 	 undesirable cell adhesion onto the channel wall of implants,
individual multilayers and their overall stacking arrangement 	 while simultaneously releasing the protein from the scaffolds
form the MPL, which are two key functions that control the 25 in a controlled manner. Depending on the number of bilayers
sustained release of proteins. The number of bilayers is also a 	 of PAA/PEG and protein/PEG sandwiched and their arrange-
key function in controlling the cytophobicity or cytophilicity	 ment, the amount of time for MPL to degrade and the cell
of these MPLs (discussed below). H-bonded PAA/PEG mul- 	 resistant nature can be tuned. To demonstrate the cytophobic
tilayers degrade upon immersing in neutral pH solution, and	 effect of the PAA/PEG MPL coatings, FIG. 25 shows fibro-
sandwiches with lower number of bilayers may degrade at a 3o blast adhesion behavior on PAA/PEG multilayers deposited
slower rate (Ono and Decker, Nanoletters, 2006). Degrada-	 on a plane glass substrate.
tion of the bilayers releases the protein along with PAA and 	 Poly(styrene sulphonate)/Poly(diallyldimethylammonium
PEG into solution. The degree of binding of protein to PEG or 	 chloride) (SPS/PDAC) represents a multilayer system which
PAA in solution after MPL degradation would essentially 	 is non-biodegradable and non-biocompatible, however it pro-
depend on the isoelectric point of protein, local concentration 35 vides a permanent cytophobic surface to cells depending on
of PAA and PEG and the salt concentrations in the solution. 	 the number of bilayers. In contrast to PAA/PEG multilayers,
We fabricate 5 bilayers of protein/PEG multilayers and sand-	 we find these multilayers are cytophobic at a higher number
wich this multilayer between two PAA/PEG multilayers each	 of bilayers (30 bilayers onwards) and cytophilic at a lower
having 5 bilayers. Protein/PEG multilayers are sandwiched 	 number of bilayers. This cytophobic/cytophilic effect of
for at least three consecutive cycles/times in the same MPL, 40 (SPS/PDAC) multilayers does not change over time, since
thus forming at least 30 bilayers, cumulatively, in a MPL to 	 these films are non-biodegradable. BPEI(SPS/PDAC) multi-
achieve time-controlled release of required amounts of pro- 	 layers may be coated onto the agarose hydrogels to provide
tein at the lesion site. In the present inventive design, the 	 long term cytophobicity to the adhesion of undesirable cells
protein in a neurotrophic factor, although one of skill in the art 	 to the surface of the scaffold in vivo. FIG. 26 shows two
will easily realize that other proteins (such as NGF) are pos-  45 micrographs of images of BPEI(SPS/PDAC) multilayer coat-
sible.	 ings fabricated onto agarose matrices. The images were taken
The basic interactions employed to form MPL on agarose	 after partial ambient drying of the agarose-multilayer struc-
hydrogels are hydrophobic and H-bond interactions. To ini- 	 tures. FIG. 27 shows fibroblast adhesion behavior on (PDAC/
tiate the MPL formation process on the agarose matrix, a 	 SPS) multilayers on a plane glass substrate.
polymer with hydrophobic characteristics as well as H-bond 50	 (SPS/PDAC) multilayers are formed on agarose hydrogel
forming capabilities, such as a branched polyethylenimine 	 scaffolds using BPEI as the initiating hydrophobic compo-
(BPEI), is required. To maintain the complete biocompatibil-	 nent and H-bonding polymer on the agarose matrix. Subse-
ity of the scaffolds, protein is used as the MPL initiating 	 quently, SPS is deposited as the negative polyelectrolyte over
polymer and subsequently the sandwiched multilayers of 	 BPEI. This is followed by the PDAC deposition. The whole
PAA/PEG and protein/PEG (as explained above) are fabri-  55 process is repeated, according to the previously described
cated. BPEI is used as the initiating polymer in cases where 	 layer-by-layer assembly process, until the required numbers
non-degradable multilayer formation is required to achieve	 of (PDAC/SPS) bilayers are formed. These multilayers are
long term cytophobicity (discussed below). FIG. 22 shows 	 deposited at 0.1 M NaCl salt concentration, which is similar
the protein release profiles of two separate MPLs; one initi- 	 to the physiological level of salt concentration.
ated with BPEI and other initiated with protein. 	 60	 MPL's containing neurotrophic factors can be deposited
Considering that the thickness of MPL ranges between	 on the surface of the nerve guidance implants by immersion in
100-500 mu, we believe that the initial phase of the multilayer 	 monomer baths for pre-determined times and in alternating
deposition occurs within the intrinsic pores of the agarose gel 	 sequences. Deposition typically occurs in deposition baths at
which usually ranges from a few nanometers to a few hundred 	 a pH of 3-4, which the growth factors can typically withstand.
nanometers. Subsequently, in the later stages of the deposi- 65	 After coating, the surface-modified implants are sterilized
tion with increasing number of bilayers, the film formation	 and can be implanted in the body. The MPL's initiate degra-
may be occurring on the outer surface of the agarose matrix. 	 dation upon implantation into the lesion site, the rate of which
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can be controlled by the number of MPL layers, or by alter-
nating layers of MPL's. Thus, timing and or sustaining the
release of neurotrophic factors are possible with this
approach. Additionally, the MPL technology is expected to
improve biocompatibility by functionalizing or passivating
the surface of agarose hydrogels such that they are less likely
to elicit an immune response.
The foregoing described embodiments depict different
components contained within, or connected with, different
other components. It is to be understood that such depicted
architectures are merely exemplary, and that in fact many
other architectures can be implemented which achieve the
same functionality. In a conceptual sense, any arrangement of
components to achieve the same functionality is effectively
"associated" such that the desired functionality is achieved.
Hence, any two components herein combined to achieve a
particular functionality can be seen as "associated with" each
other such that the desired functionality is achieved, irrespec-
tive of architectures or intermedial components. Likewise,
any two components so associated can also be viewed as
being "operably connected", or "operably coupled", to each
other to achieve the desired functionality.
While particular embodiments of the present invention
have been shown and described, it will be obvious to those
skilled in the art that, based upon the teachings herein,
changes and modifications may be made without departing
from this invention and its broader aspects and, therefore, the
appended claims are to encompass within their scope all such
changes and modifications as are within the true spirit and
scope of this invention. Furthermore, it is to be understood
that the invention is solely defined by the appended claims. It
will be understood by those within the art that, in general,
terms used herein, and especially in the appended claims
(e.g., bodies of the appended claims) are generally intended
as "open" terms (e.g., the term "including" should be inter-
preted as "including but not limited to," the term "having"
should be interpreted as "having at least," the term "includes"
should be interpreted as "includes but is not limited to," etc.).
It will be further understood by those within the art that if a
specific number of an introduced claim recitation is intended,
such an intent will be explicitly recited in the claim, and in the
absence of such recitation no such intent is present. For
example, as an aid to understanding, the following appended
claims may contain usage of the introductory phrases "at least
one" and "one or more" to introduce claim recitations. How-
ever, the use of such phrases should not be construed to imply
that the introduction of a claim recitation by the indefinite
articles "a" or "an" limits any particular claim containing
such introduced claim recitation to inventions containing
only one such recitation, even when the same claim includes
the introductory phrases "one or more" or "at least one" and
indefinite articles such as "a" or "an" (e.g., "a" and/or "an"
should typically be interpreted to mean "at least one" or "one
or more"); the same holds true for the use of definite articles
used to introduce claim recitations. In addition, even if a
specific number of an introduced claim recitation is explicitly
recited, those skilled in the art will recognize that such reci-
tation should typically be interpreted to mean at least the
recited number (e.g., the bare recitation of "two recitations,"
without other modifiers, typically means at least two recita-
tions, or two or more recitations).
Accordingly, the invention is not limited except as by the
appended claims.
The invention claimed is:
1. A method for manufacturing a biocompatible neurologi-
cal platform comprising:
immersing a matrix into a first solution, the matrix com-
prising a first polymer surrounding a plurality of second
polymer members arranged in a desired distribution pat-
20
tern within the first polymer with each of the plurality of
second polymer members having a predetermined
length, cross-sectional area and cross-sectional shape,
the first polymer being soluble in the first solution, the
5 plurality of second polymer members being soluble in a
second solution incorporating acetonitrile and insoluble
in the first solution wherein the first solution dissolves
the surrounding first polymer;
immersing the plurality of members in a third solution in
10	 which the plurality of members are insoluble, the third
solution forming a biocompatible matrix surrounding
the plurality of members;
centrifuging the plurality of members immersed in the
third solution; and
15	 immersing the plurality of members and surrounding bio-
compatible matrix in the second solution to thereby dis-
solve the plurality of members and create an array of
pores disposed in the biocompatible matrix, wherein the
pores are defined by adjacent hollow chambers compris-
20	 ing walls of less than about 200 micrometer thickness,
whereby the biocompatible neurological platform is
formed and comprises:
a scaffold comprising a biocompatible material having first
and second ends and a predetermined length;
25	 the array of pores disposed in the scaffold and extending
from the first end to the second end, wherein the pores
are defined by adjacent hollow chambers comprising
walls of less than about 200 micrometer thickness; and
a reservoir disposed in the scaffold adapted for the time-
30	 release deployment of at least one neurotrophic agent.
2. The method of claim 1 wherein the first polymer is
selected from a group of polymers comprising a polymethyl-
methacrylate polymer, a polystyrene polymer, and a polyvi-
nyl alcohol polymer.
35 3. The method of claim 2 wherein the first solution com-
prises polypropylene carbonate if the selected first polymer
comprises polymethylmethacrylate, and comprises tetrahy-
drofuran if the selected first polymer comprises polystyrene,
and comprises water if the selected first polymer comprises
40 polyvinyl alcohol.
4. The method of claim 1 wherein the plurality of second
polymer members are selected from a group of polymers
comprising a polymethylmethacrylate polymer, a polysty-
rene polymer, and a polyvinyl alcohol polymer.
45 5. The method of claim 4 wherein the second solution
comprises polypropylene carbonate if the selected second
polymer members comprises polymethylmethacrylate, and
comprises tetrahydrofuran if the selected second polymer
members comprises polystyrene, and comprises water if the
50 selected second polymer members polyvinyl alcohol.
6. The method of claim 1 wherein the third solution is a
biocompatible gel in liquid form.
7. The method of claim 1, wherein the biocompatible neu-
rological platform is adapted to be surgically implanted in a
55 spinal column.
8. The method of claim 7, further comprising placing a
neurotrophic agent in at least a portion of the pores.
9. The method of claim 1 wherein the biocompatible matrix
has face dimensions exceeding 1 cm2 and the conduits exceed
60 1 cm in length.
10. The method of claim 1, further comprising the step of
deploying the scaffold inside an outer reinforcing tube.
11. The method of claim 10, wherein the outer reinforcing
tube is constructed of TYGON® (polyvinyl chloride thermo-
65 plastic polymer) medical tubing.
12. The method of claim 1, wherein the method includes
coating the scaffold with a polyelectrolyte layer.
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13. The method of claim 12, wherein the polyelectrolyte
layer is a multifunctional polyelectrolyte layer.
14. The method of claim 13, wherein a neurotrophic factor
is incorporated in the multifunctional polyelectrolyte layer.
15. The method of claim 13, wherein the multifunctional
polyelectrolyte layer is a polyacrylic acid/polyethylene gly-
col multilayer.
16. The method of claim 13, wherein the multifunctional
polyelectrolyte layer is a poly(styrene sulphonate)/poly(dial-
lyldimethylammonium chloride) multilayer.
17. A biocompatible neurological platform comprising:
a scaffold comprising a biocompatible material having first
and second ends and a predetermined length;
an array of pores disposed in the scaffold and extending
from the first end to the second end, wherein the pores
are defined by adjacent hollow chambers comprising
walls of less than about 200 micrometer thickness; and
a reservoir disposed in the scaffold adapted for the time-
release deployment of at least one neurotrophic agent.
18. The platform of claim 17 wherein the pores are further
defined by an aspect ratio greater than 10.
19. The platform of claim 17 wherein the pores are further
defined by an aspect ratio greater than 150.
20. The platform of claim 17, wherein the neurotrophic
agent is selected from the group consisting of brain derived
neurotrophic factor and brain derived neurotrophic factor
secreting marrow stromal cells.
21. The platform of claim 17, wherein the scaffold is
deployed inside an outer reinforcing tube.
22
22. The platform of claim 21, wherein the outer reinforcing
tube is constructed of TYGON® (polyvinyl chloride thermo-
plastic polymer) medical tubing.
23. The platform of claim 17, wherein the scaffold is coated
5 with a polyelectrolyte layer.
24. The platform of claim 23, wherein the polyelectrolyte
layer is a multifunctional polyelectrolyte layer.
25. The platform of claim 24, wherein a neurotrophic factor
is incorporated in the multifunctional polyelectrolyte layer.
10 26. The platform of claim 24, wherein the multifunctional
polyelectrolyte layer is a polyacrylic acid/polyethylene gly-
col multilayer.
27. The platform of claim 24, wherein the multifunctional
polyelectrolyte layer is a poly(styrene sulphonate)/poly(dial-
15 lyldimethylammonium chloride) multilayer.
28. The platform of claim 17, wherein the wall thickness is
less than about 100 micrometers.
29. The platform of claim 17, wherein the wall thickness is
less than about 50 micrometers.
20	 30. The platform of claim 17, wherein the wall thickness is
less than about 40 micrometers.
31. The platform of claim 17, wherein the device is more
than about 40 millimeters along the longest dimension of the
device.
25 32. The platform of claim 17, wherein the device is more
than about 100 millimeters along the longest dimension
device.
